Other ways to search: Events Calendar | UTHSC

The Department of Pharmacology, Addiction Science and Toxicology Virtual Seminar

|

Guest Speaker: Falk Lohoff, M.D.

Lasker Clinical Research Scholar

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institutes of Health

Section of Clinical Genomics and Experimental Therapeutics

 

Title: Epigenetics of Alcohol Use Disorder – Identification of PCSK9 as novel target

 

Summary:

“My research group is interested in translational research that advances the understanding and treatment of Alcohol Use Disorder (AUD). We use various molecular discovery strategies (-omics approaches) starting out in human, most recently epigenome-wide association studies (EWAS)/epigenomics, to identify novel targets for AUD. Top targets are then validated using endophenotypic human studies and animal models for proof-of-concept mechanistic and novel therapeutic studies. This strategy has recently led to the exciting discovery of the proprotein convertase subtilisin/kexin 9 (PCSK9) gene being abnormally regulated in AUD/alcohol-associated liver disease (ALD). Subsequent animal work has investigated the molecular mechanisms of PCSK9 dysregulation in models of chronic alcohol exposure. In addition, we have used animal models of chronic alcohol exposure to test novel PCSK9 inhibitors with striking results demonstrating attenuation of alcohol-associated liver disease pathology and overall anti-inflammatory responses. These data have directly led to a pilot human clinical trial at the NIH intramural program that is currently undergoing IRB review and will start shortly (A Phase I, Randomized, Double-Blind, Placebo-Controlled, Study of Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers).By better understanding the molecular landscape of AUD, will enable us to develop novel targets for treatment efforts of AUD, an aera of critical importance and significant unmet clinical need, given that there are currently only 3 FDA approved medication for AUD and 0 for alcohol-associated liver disease (ALD).”

 

Date: Wednesday, December 2, 2020

Time: 12:00pm CT (US and Canada)

Fuming Zhou is inviting you to a scheduled Zoom meeting.

Topic: Pharmacology Seminar: Dr. Lohoff, NIH/NIAAA: Epigenetics of Alcohol Use Disorder

Time: Dec 2, 2020 11:45 AM Central Time (US and Canada)

Join Zoom Meeting

https://us02web.zoom.us/j/89880383007?pwd=Qk9EeEJJNko1c1ZTdmw4ZEFrZE1VUT09

Meeting ID: 898 8038 3007

Passcode: 5FiJdd